Knowledge, attitude and participation of hospital pharmacists in adverse drug reaction monitoring and reporting in Ibadan, southwest Nigeria
Main Article Content
Abstract
Background: Pharmacists as a significant member of healthcare team are expected to play a pivotal role in adverse drug reaction (ADR) detection, monitoring and reporting. However, pharmacists have been found to inconsistently engage in this practice, thereby underscoring the need for periodic evaluation of their participation in core-aspects of ADRs.
Objective: To assess knowledge, attitude and participation of pharmacists in 11-public hospitals in Ibadan, southwestern Nigeria in ADR detection, monitoring and reporting.
Method: This was a questionnaire-guided cross-sectional survey among pharmacists in the 11-selected hospitals. Demographic information, general knowledge in ADRs, as well as attitude and participation in ADR detection, monitoring and reporting were assessed. Data were summarised using descriptive statistics, while categorical variables were evaluated using Chi-square ( 2) test at p<0.05.
Results: All the 37 participants completely responded to the question-items. Twenty-one (56.8%) had 1-10 years' practice experience and 24 (65.0%) had prior ADR-related training. Overall, 17 (45.9%) had 'adequate' knowledge, 28 (75.1%) demonstrated 'positive' attitude, and 17 (45.9%) showed 'high' level of participation in ADR detection and monitoring. Prior training in ADR-reporting significantly influenced knowledge ( 2=4.220, p=0.04) and attitude ( 2=9.489, p=0.004).
Conclusion: The general knowledge of hospital pharmacists about ADRs and reporting is relatively moderate. Approximately three-quarters show positive attitude towards ADR reporting, and nearly half exhibit high level of participation. There is generally a need for consistent training and re-training of hospital pharmacists in the coreconcept of ADRs and ADR-reporting, as this may help in bridging the knowledge and practice gaps to enhance reporting rate.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
How to Cite
Share
References
Al Hail M, Elkassem W, Hamad A, Abdoulrouf P, Thomas B, Stewart D (2018). Overview of pharmacovigilance practices at the largest
academic healthcare system in the state of Qatar. International Journal of Clinical Pharmacy 40: 769-774.
Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, Farrar K, Park BK, Breckenndge AM (2004). Adverse drug reactions as cause of admission to hospital: prospective analysis of 18820 patients. British Medical Journal 329(7456): 15-19.
Olowofela A, Fourrier-Re?glat A, Isah AO (2016). Pharmacovigilance in Nigeria: An Overview. Pharmaceutical Medicine 30(2): 87-94.
Olowofela AO, Isah AO (2017). A Profile of adverse effects of antihypertensive medicines in a tertiary care clinic in Nigeria. Annals of African Medicine 16(3): 114-119.
Meier F, Maas R, Sonst A, Patapovas A, Mu?ller F, Plank-Kiegele B, Pfistermester B, Schoffski O, Burkle T, Durmann H (2015). Adverse drug events in patients admitted to an emergency department: an analysis of direct costs. Pharmacoepidemiology and Drug Safety 24(2): 176-186.
Pal SN, Duncombe C, Falzon D, Olsson S (2013). WHO strategy for collecting safety data in public health programmes: complementing spontaneous reporting systems. Drug Safety 36: 75-81.
National Pharmacovigilance Centre, NAFDAC, Nigeria. Safety of medicines in Nigeria, Guide for reporting adverse drug reaction to marketed drugs. First edition 2012-1. Available at; http://www.nafdacnigeria.org/pharmacovigilance,html. Accessed 15 May, 2019.8. National Agency for Food and Drug, Administration and Control, Pharmacovigilance, 2017. Available at http://www.nafdac.gov.ng/index.php/aboutnafdac/faqs/pharmacovigilance. Accessed 15 May, 2019.
Elshafie S, Zaghloul I, Roberti AM (2018). Pharmacovigilance in developing countries (part 1): importance and challenges. International Journal of Clinical Pharmacy 40: 758-763.
Harmark L, van Grootheest AC (2018). Pharmacovigilance: methods, recent developments and future perspectives. European Journal of
Clinical Pharmacology 64: 743-52.
Elshafie S, Roberti AM, Zaghlgul I (2018). Pharmacovigilance in developing countries (Part II): a path forward. International Journal of Clinical Pharmacy 40: 764-768.
Okezie OO, Fawole OI (2008). Adverse drug reactions reporting by physicians in Ibadan, Nigeria. Pharmacoepidemiology and Drug Safety 17: 517522.
Inman WH (1996). Attitudes to adverse drug reaction reporting. British Journal of Clinical Pharmacology 41(5): 434-435.
Lopez-Gonzalez E, Herdeiro MT, Figueiras A (2009). Determinants of under-reporting of adverse drug reactions. Drug Safety 32(1): 19-31.
British Medical Association Board of Sciences: Reporting adverse drug reactions- a guide for healthcare professionals. May 2006. Available at http://www.isopouline.org/wp-content/uploads/2015/01/BMAreport.pdf. Accessed 19 May, 2019.
Balidemaj F (2013). Adverse drug reactions problems with spontaneous reporting systems and communicating information to providers to improve reporting rate globally. Working paper from the University of Oxford. Available at http://universumks.org/wp content/uploads/2014/09/Balideng-003-2013pdf. Accessed 19 May, 2019.
Reza RCM, Emmerton L (2015). An introduction to adverse drug reaction reporting systems in different countries. International Journal of Pharmacy Practice 13: 91-100.
van Grootheest AC, de Jong-van den Berg LT (2005). The role of hospital and community pharmacists in pharmacovigilance. Research in Social and Administrative Pharmacy 1(1): 126-33.
Dehi-Gedde A, Harg P, Stenberg-Nilsen H, Buajordet M, Granas AG, Horn AM (2007). Characteristics and quality of adverse drug reaction reports by pharmacists in Norway. Pharmacoepidemiology and Drug Safety 16(9): 999-1005.
Said ASA, Hussain N (2017). Adverse drug reaction practices among United Arab Emirates Pharmacists and Prescribers. Hospital Pharmacy 52(5): 361-366.
Mahmoud MA, Alswaida Y, Alshammari T, Khan TM, Alrasheedy A, Hassali MA, Aljadhey H (2014). Commuinty pharmacist's knowledge, behaviours and experiences about adverse drug reaction reporting in Saudi Arabia. Saudi Pharmaceutical Journal 22: 411-8.
Ahmad A, Patel I, Balkrishnan R, Mohanta GP, Manna PK (2013). An evaluation of knowledge, attitude and practice of Indian pharmacists towards adverse drug reaction reporting: A pilot study. Perspective in Clinical Research 4(4): 204-210.
Udoye JA, Ozolua RI, Nwokike J (2018). Assessment of the knowledge, attitude and practice of pharmacovigilance by pharmacists in two states in south-eastern Nigeria. Tropical Journal of Pharmaceutical Research 17(5): 937-945.
Fadare JO, Enwere OO, Afolabi A, Chedi B, Musa A (2011). Knowledge, attitude and practice of adverse drug reaction reporting among healthcare workers in a tertiary centre in Northern Nigeria. Tropical Journal of Pharmaceutical Research 10(3): 235-242.
Oreagba I, Ogunleye O, Olayemi S (2011). The knowledge, perceptions and practice of Pharmacovigilance amongst community pharmacists in Lagos state, south west Nigeria. Pharmacoepidemiology and Drug Safety 20(1): 30-5.
Green CF, Mottram DR, Rowe PH, Pirmohamed M (2001). Attitudes and knowledge of hospital pharmacists to adverse drug reaction reporting. British Journal of Clinical Pharmacology 51(1): 81-86.
Ezeuko, A.Y., Ebenebe, U., Nnebue, C.C. and Ugoji, J.O (2015). Factors associated with the reporting of adverse drug reactions by health workers in Nnewi Nigeria. International Journal of Preventive Medicine 6: 25.
Alraie NA, Saad AA, Sabry NA, Farid SF (2015). Adverse drug reactions reporting: a questionnairebased study on Egyptian pharmacists' attitudes following an awareness workshop. Journal of Evaluation and Clinical Practice 22 (3): 349-55.
Irujo M, Beitia G, Bes-Rastrollo M, Figueiras A, Hernández-Díaz S, Lasheras B (2007). Factors that influence under-reporting of suspected adverse drug reactions among community pharmacists in a Spanish region. Drug Safety 30(11): 1073-1082.
Umar MT, Bello SO, Chika A, Oche OM (2016). Attitude of Nurses and Pharmacists on adverse drug reactions reporting in selected hospitals in Sokoto, North-West Nigeria. Journal of Research in Pharmacy Practice 5(3): 219-221.
Adefurin A (2011). The knowledge, perceptions and practice of pharmacovigilance amongst community pharmacists in Lagos state, South-West Nigeria - flaws with the methodology. Pharmacoepidemiology and Drug Safety 20(6): 657-658.
Knapp HK, Katzman H, Hambright JS, Albrant DH (1998). Community pharmacist intervention in a pharmacy benefit contract. American Journal of Health System Pharmacist 55(1): 41-45.
Jha N, Rathore DS, Shankar PR, Bhandary S, Pandit RB, Gyawali S, Alshakka M (2017). Effect of an educational intervention on knowledge and attitude regarding pharmacovigilance and consumer pharmacovigilance among community pharmacists in Lalitpur district, Nepal. BioMedical Central Research Notes 104: 1-8.
Raosoft Sample Size Calculator. Available at http://www.raosoft.com/samplesize.html Accessed 20 December, 2018.
Seid MA, Kasahun AE, Mante BM, Gebremaham SN (2018). Healthcare professional knowledge, attitude and practice towards adverse drug reaction reporting at the health center level in Ethiopia. International Journal of Clinical Pharmacy 40: 895-902.
Adisa R, Anifowose AT (2019). Pharmacists' knowledge, attitude and involvement in palliative care in selected tertiary hospitals in southwestern Nigeria. BioMedical Central Palliative Care 18: 107 https://doi.org/10.1186/s12904-019-0492-8.
Akande-Sholabi W, Ogundipe FS, Adisa R (2020). Pharmacists' knowledge and counselling on fall risk increasing drugs in a tertiary teaching hospital in Nigeria. BioMedical Central Health Services Research 20:259 https://doi.org/10.1186/s12913-020-05140-6
Adisa R, Omitogun TI (2019). Awareness, knowledge, attitude and practice of adverse drug reaction reporting among health workers and
patients in selected primary healthcare centres in Ibadan, southwestern Nigeria. BioMedical Central Health Services Research 19:926 https://doi.org/10.1186/s12913-019-4775-9.
Chinenye IU, Micheal OU (2012). Health workers and hospital patients' knowledge of pharmacovigilance in sokoto, North-west Nigeria. Nigerian Journal Pharmaceutical Sciences 11(2): 31-40.
Almandil NB (2016). Healthcare professional awareness and knowledge of adverse drug reactions and pharmacovigilance. Saudi Medical Journal 37(12): 1359-1364
Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, Janecek E, Domecq C, Greenblatt DJ (1981). A method for estimating the probability of adverse drug reactions. Clinical Pharmacy and Therapeutics 30(2): 239-245.
The use of the WHO-UMC system for standardized case causality assessment. Available at http://www.who-umc.org/graphics/4409.pdf.
Accessed 30 May, 2019.
Osakwe A, Oreagba T, Adewumi AJ, Adekoya A, Fajolu I (2013). Impact of training on Nigerian healthcare professionals' knowledge and practice of pharmacovigilance. International Journal of Risk and Safety of Medicine 25(4): 219-27.
Su C, Ji H, Su Y (2010). Hospital pharmacists' knowledge and opinions regarding adverse drug reaction reporting in Northern China. 19(3): 217-222.
Martins SF, vanMil JWF, da Costa FA (2005). The organizational framework of community pharmacies in Europe. International Journal of
Clinical Pharmacy 37: 896-905.
Smith M, Bates DW, Bodenheimer T, Cleary PD (2010). Why Pharmacists belong in the Medical home. Health Affairs 29(5): 906-913.
Herdeiro MT, Polonia J, Gesta-otero JJ, Figueiras A (2018). Improving the reporting of adverse drug reactions: a cluster-randomised trial among pharmacists in Portugal. Drug Safety 31: 335-44
Li R, Curtain C, Bereznicki L, Zaidi STR (2018). Community pharmacists' knowledge and perspectives of reporting adverse drug reaction in
Australia: a cross-sectional survey. International Journal of Clinical Pharmacy 40: 878-889.